上个世纪末期,卵巢癌的临床处理出现了三大进展,即将手术病理分期作为卵巢癌的分期标准,肿瘤细胞减灭术作为晚期卵巢癌手术原则,以及紫杉醇+铂类作为卵巢上皮性癌一线化疗方案。由于这三大进展的出现,卵巢癌的5年生存率已由30%上升为50%[1]。其中可获得长期缓解的患者约占25%~3 The late last century, clinical treatment of ovarian cancer there have been three major advances, the surgical staging of ovarian cancer as staging criteria, cytoreductive surgery as a principle of advanced ovarian cancer surgery, and paclitaxel + platinum as epithelial ovarian cancer line Chemotherapy. Due to these three major advances, the 5-year survival rate of ovarian cancer has risen from 30% to 50% [1]. Among them, about 25% ~ 3 patients can get long-term remission